Connect
← Return to Multifocal Adenocarcinoma of the lung, continual recurrences
Discussion
Multifocal Adenocarcinoma of the lung, continual recurrences
Lung Cancer | Last Active: 2 days ago | Replies (458)Comment receiving replies
@vic83 Good Morning! My first cancer was in my upper right lobe and the whole lobe was removed with the “big” surgery. At that point, it was not known that I had multifocal lung cancer, and, that was the gold standard.
3 years later, I had a ggo begin to grow and the surgeries going forward were all VATS wedges.
I am not a doctor. It’s my understanding that with multifocal lung cancer, the objective is to preserve lung tissue, as this is an ongoing disease, and I would look to your team to manage your care. Best wishes and prayers for you this year.
Replies to "@vic83 Good Morning! My first cancer was in my upper right lobe and the whole lobe..."
Connect
STUDY Treatment of Multifocal Lung Adenocarcinoma/Mayo Clinic
This study started in 2013 and was due out in Oct 2023. It seems it is delayed since now estimated to be complete in Oct 2025
https://clinicaltrials.gov/study/NCT01946100
Study Overview: To gather preliminary safety and outcome data for the multimodality treatment of lung adenocarcinoma in the setting of multifocal BAC.
Detailed Description
Lung bronchoalveolar carcinoma (BAC) or adenocarcinoma in situ (AIS) continues to represent a poorly understood clinical entity. A frequent clinical dilemma in lung cancer care is the management of a documented or suspected invasive adenocarcinoma in the setting of multifocal ground glass opacity (GGO) consistent with multifocal AIS. These patients are typically classified as stage IV disease, and treated with palliative chemotherapy. No existing pathologic or molecular test is currently capable of making the distinction between independent primary versus metastatic tumors, a distinction for which substantial treatment impact exists. Many treating physicians suspect that outcomes for this specific patient subgroup are better than norms for stage IV disease, as such patients are frequently node-negative and without distant metastases despite multiple lesions present. To address this issue, we will evaluate a multimodality treatment protocol using aggressive local and targeted systemic therapy for multifocal lung adenocarcinoma, incorporating information from tumor genome sequencing for individualized treatment planning. The results will have significant impact in advancing the biologic understanding and treatment approach for lung adenocarcinoma in the setting of multifocal AIS.